title: Treatment of hypertension in obese patients.
abstract: Obesity is a global pandemic and with its rise, its associated co-morbidities are increasing in prevalence, particularly uncontrolled hypertension. Lifestyle changes should be an anchor for the management of obesity-related hypertension; however, they are difficult to sustain. Drug therapy is often necessary to achieve blood pressure control. Diuretics, inhibitors of the renin-angiotensin system, and dihydropyridine calcium channel blockers are often used as first trio, with subsequent additions of mineralocorticoid receptor antagonists and/or dual alpha/beta blocking agents. While a number of agents are currently available, 50 % of hypertensive patients remain uncontrolled. A number of novel drug and invasive therapies are in development and hold significant potential for the effective management of obesity-related hypertension.
authors.affiliation: Division of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. skidambi@mcw.edu
authors.forename: Srividya
authors.initials: S
authors.lastname: Kidambi
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Kotchen
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D009765:Obesity / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents; D000959:Antihypertensive Agents